India
· Delayed Price · Currency is INR Aarti Drugs Statistics
Total Valuation
Aarti Drugs has a market cap or net worth of INR 33.63 billion. The enterprise value is 39.23 billion.
| Market Cap | 33.63B |
| Enterprise Value | 39.23B |
Important Dates
The next estimated earnings date is Wednesday, April 30, 2025.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | Feb 4, 2025 |
Share Statistics
Aarti Drugs has 91.94 million shares outstanding. The number of shares has decreased by -0.87% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 91.94M |
| Shares Change (YoY) | -0.87% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 46.60% |
| Owned by Institutions (%) | 16.31% |
| Float | 35.72M |
Valuation Ratios
The trailing PE ratio is 21.91 and the forward PE ratio is 23.60. Aarti Drugs's PEG ratio is 1.57.
| PE Ratio | 21.91 |
| Forward PE | 23.60 |
| PS Ratio | 1.44 |
| PB Ratio | 2.63 |
| P/TBV Ratio | 2.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.57 |
Enterprise Valuation
| EV / Earnings | 25.71 |
| EV / Sales | 1.68 |
| EV / EBITDA | 13.59 |
| EV / EBIT | 16.58 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.46 |
| Debt / EBITDA | 2.04 |
| Debt / FCF | n/a |
| Interest Coverage | 6.60 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 8.07% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 21.90M |
| Profits Per Employee | 1.43M |
| Employee Count | 1,064 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.04% in the last 52 weeks. The beta is 0.70, so Aarti Drugs's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -27.04% |
| 50-Day Moving Average | 361.94 |
| 200-Day Moving Average | 457.41 |
| Relative Strength Index (RSI) | 56.30 |
| Average Volume (20 Days) | 20,322 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aarti Drugs had revenue of INR 23.30 billion and earned 1.53 billion in profits. Earnings per share was 16.69.
| Revenue | 23.30B |
| Gross Profit | 8.09B |
| Operating Income | 2.37B |
| Pretax Income | 2.05B |
| Net Income | 1.53B |
| EBITDA | 2.87B |
| EBIT | 2.37B |
| Earnings Per Share (EPS) | 16.69 |
Balance Sheet
The company has 295.60 million in cash and 5.90 billion in debt, giving a net cash position of -5.61 billion or -60.97 per share.
| Cash & Cash Equivalents | 295.60M |
| Total Debt | 5.90B |
| Net Cash | -5.61B |
| Net Cash Per Share | -60.97 |
| Equity (Book Value) | 12.78B |
| Book Value Per Share | 139.96 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 34.70%, with operating and profit margins of 10.15% and 6.55%.
| Gross Margin | 34.70% |
| Operating Margin | 10.15% |
| Pretax Margin | 8.79% |
| Profit Margin | 6.55% |
| EBITDA Margin | 12.30% |
| EBIT Margin | 10.15% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 0.27%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 0.27% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.87% |
| Shareholder Yield | 1.15% |
| Earnings Yield | 4.54% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on September 30, 2020. It was a forward split with a ratio of 4.
| Last Split Date | Sep 30, 2020 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |